{"id":372001,"date":"2024-01-02T14:00:00","date_gmt":"2024-01-02T13:00:00","guid":{"rendered":"https:\/\/medizinonline.com\/proven-local-therapy-with-spray-foam-new-study-data\/"},"modified":"2024-01-02T14:00:30","modified_gmt":"2024-01-02T13:00:30","slug":"proven-local-therapy-with-spray-foam-new-study-data","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/en\/proven-local-therapy-with-spray-foam-new-study-data\/","title":{"rendered":"Proven local therapy with spray foam – new study data"},"content":{"rendered":"\n

In a prospective, non-interventional multi-center study, the treatment effects of calcipotriol\/betamethasone dipropionate (Cal\/Bet) spray foam in patients with scalp psoriasis were investigated in a “real-world” setting. This topical therapy option was not only convincing in terms of efficacy, but also proved to be well tolerated. This finding is consistent with earlier evidence.<\/strong><\/p>\n\n\n\n

Up to 80% of psoriasis patients have scalp involvement [1,2]. The treatment of capillitium is often a challenge. In addition to efficacy, the most important factor with regard to patient adherence is good acceptance of the formulation of the preparation [3]. Fixed combinations of calcipotriol\/betamethasone dipropionate (Cal\/Bet) are established topical therapy options for the treatment of psoriasis capitis. Compared to their use as monosubstances, cal\/bet fix combinations have additive effects in terms of reducing the hyperproliferation of keratinocytes and inflammatory processes [3,4]. Betamethasone also reduces the local side effects of calcipotriol (lower risk of skin atrophy and burning) [3,4].<\/p>\n\n

Current Swiss treatment pathway recommends topical therapy
with Cal\/Bet fixed combinations <\/strong>
The Swiss treatment pathway for topical psoriasis therapy published in 2021 points out that the Cal\/Bet spray foam (Enstilar\u00ae<\/sup>) has repeatedly proven its effectiveness in the treatment of scalp psoriasis [3,8\u201310,11]. The foam spray formulation has good patient acceptance and proved to be an effective treatment option. The induction therapy (2-4 weeks) is followed by the maintenance phase, during which the frequency of application can be reduced to twice a week. Depending on patient preference, a switch to the Cal\/Bet fixed combination in gel form (Daivobet\u00ae<\/sup> Gel, Xamiol\u00ae<\/sup>) can also be considered [3,11]. The fixed combinations of calcipotriol plus betamethasone dipropionate, which are available as a spray foam and gel, are well tolerated and completely free of water and alcohol. The correct application procedure at the capillitium should be discussed with the patient before starting treatment. <\/td><\/tr><\/tbody><\/table><\/figure>\n\n

CAPITIS study underpins evidence base <\/h3>\n\n

The observational study included 217 adults with scalp psoriasis from 96 centers in Germany [5,6]. 53.4% of patients treated with Cal\/Bet spray foam for 4 weeks achieved a scalp BSA <10% and a mild scalp PGA. The mean change in scalp PGA after 4 weeks of treatment with Cal\/Bet spray foam is shown in Figure 1 <\/strong>[6]. The proportion of patients with a mild case increased from 12.4% (n=24) to 85.5% (n=165), while the rate of those with a moderate or severe case fell from 58.0% and 29.5% to 11.9% and 2.6% respectively. In addition, 47.6% of patients achieved a PSSI \u22642. A reduction in pruritus and other symptoms (induration, erythema and scaling) was already observed after day 3. The quality of life of patients treated with Cal\/Bet spray foam improved from a DLQI of 9.6 (SD \u00b1 5.5) at baseline to 2.8 (\u00b1 3.5) after 4 weeks. The proportion of patients with a DLQI 0\/1 increased from 3.2% at baseline to 47.9% at the end of the study. Patient satisfaction was high, as reflected in TSQM-9 scores of 74.5 (\u00b1 27.1) for efficacy, 72.0 (\u00b1 25.2) for ease of use and 77.8 (\u00b1 24.2) for overall satisfaction. 97.4% of the treating physicians rated the tolerability of the Cal\/Bet spray foam as good or very good and no new safety-relevant signals were reported. <\/p>\n

\n
\"\"<\/a><\/figure>\n<\/div>\n

In summary, the results of this observational study confirm the favorable risk-benefit profile of this treatment option in patients with scalp psoriasis. <\/p>\n\n

Congress: DDG Annual Conference <\/em><\/p>\n\n

<\/p>\n\n

Abbreviations<\/strong>
Scalp-BSA=Scalp-Body Surface Area
Scalp PGA = Scalp Physician’s Global Assessment
PSSI=Psoriasis Scalp Severity Index
DLQI = Dermatology Life Quality Index
TSQM=Treatment Satisfaction Questionnaire for Medication<\/em><\/td><\/tr><\/tbody><\/table><\/figure>\n\n

Literature:<\/p>\n\n

    \n
  1. Schlager JG, et al: Cochrane Database Syst Rev 2016 Feb; 2: CD009687.<\/li>\n\n\n\n
  2. Chan CS, et al: JAAD 2009; 60(6): 962-971. <\/li>\n\n\n\n
  3. Maul J-T, et al: Dermatology 2021; 237: 166-178.<\/li>\n\n\n\n
  4. Segaert S, Ropke M: J Drugs Dermatol 2013; 12(8): e129-137. <\/li>\n\n\n\n
  5. Staubach-Renz P, et al: CAPITIS study, P083. Volume of abstracts, DDG conference, 26-29.04.2023.<\/li>\n\n\n\n
  6. Staubach P, et al: Dermatology 2023; 239(2): 206-216. <\/li>\n\n\n\n
  7. Ortonne J, et al: JEADV 2009; 23(12): 1435-1444<\/li>\n\n\n\n
  8. Paul C, et al: JEADV 2017; 31(1): 119-126.<\/li>\n\n\n\n
  9. Lebwohl M, et al: JCAD 2016; 9(2): 34-41.<\/li>\n\n\n\n
  10. Anderko M, et al: Clin Cosmet Investig Dermatol 2019; 12: 699-705.<\/li>\n\n\n\n
  11. Drug information, www.swissmedicinfo.ch<\/a> (last accessed 15.08.2023).<\/li>\n<\/ol>\n\n

    <\/p>\n\n

    DERMATOLOGIE PRAXIS 2023; 33(6): 24 (published on 11.12.23, ahead of print)<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"

    In a prospective, non-interventional multi-center study, the treatment effects of calcipotriol\/betamethasone dipropionate (Cal\/Bet) spray foam in patients with scalp psoriasis were investigated in a “real-world” setting. This topical therapy option…<\/p>\n","protected":false},"author":7,"featured_media":305993,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Scalp psoriasis","footnotes":""},"category":[11513,11340,11480,11548,11503],"tags":[73238,17740,17737,17739,14584,12929,71897,73234,17759],"powerkit_post_featured":[],"class_list":["post-372001","post","type-post","status-publish","format-standard","has-post-thumbnail","category-congress-reports","category-dermatology-and-venereology","category-rheumatology","category-rx-en","category-studies","tag-betamethasone-dipropionate","tag-calcipotriol-en","tag-enstilar-en","tag-fixed-combination","tag-local-therapy","tag-psoriasis-capitis-en","tag-real-world-en-2","tag-scalp-psoriasis","tag-spray-foam","pmpro-has-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-04-16 09:30:28","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"en_US","wpml_translations":{"fr_FR":{"locale":"fr_FR","id":372013,"slug":"therapie-locale-eprouvee-avec-la-mousse-en-spray-nouvelles-donnees-detude","post_title":"Th\u00e9rapie locale \u00e9prouv\u00e9e avec la mousse en spray - nouvelles donn\u00e9es d'\u00e9tude","href":"https:\/\/medizinonline.com\/fr\/therapie-locale-eprouvee-avec-la-mousse-en-spray-nouvelles-donnees-detude\/"},"it_IT":{"locale":"it_IT","id":372020,"slug":"terapia-locale-comprovata-con-schiuma-spray-nuovi-dati-di-studio","post_title":"Terapia locale comprovata con schiuma spray - nuovi dati di studio","href":"https:\/\/medizinonline.com\/it\/terapia-locale-comprovata-con-schiuma-spray-nuovi-dati-di-studio\/"},"pt_PT":{"locale":"pt_PT","id":372033,"slug":"terapia-local-comprovada-com-espuma-em-spray-novos-dados-de-estudo","post_title":"Terapia local comprovada com espuma em spray - novos dados de estudo","href":"https:\/\/medizinonline.com\/pt-pt\/terapia-local-comprovada-com-espuma-em-spray-novos-dados-de-estudo\/"},"es_ES":{"locale":"es_ES","id":372045,"slug":"terapia-local-probada-con-espuma-en-spray-nuevos-datos-del-estudio","post_title":"Terapia local probada con espuma en spray: nuevos datos del estudio","href":"https:\/\/medizinonline.com\/es\/terapia-local-probada-con-espuma-en-spray-nuevos-datos-del-estudio\/"}},"_links":{"self":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/372001","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/comments?post=372001"}],"version-history":[{"count":2,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/372001\/revisions"}],"predecessor-version":[{"id":373405,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/372001\/revisions\/373405"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/media\/305993"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/media?parent=372001"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/category?post=372001"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/tags?post=372001"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/powerkit_post_featured?post=372001"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}